CME: Chronic Lymphocytic Leukemia (CLL): Updates from the 67th ASH Annual Meeting (ASH 2025)
Activity Description / Statement of Need:
In this online, self-learning activity:
Chronic lymphocytic leukemia (CLL) is a disease in which leukemic cells accumulate in the peripheral blood, bone marrow, and lymphatic tissue. Elderly patients comprise the vast majority of those diagnosed with CLL with a mean patient age of 72 years. There are over 23,000 cases in the U.S. per year, with an annual mortality rate in excess of 4,400. CLL may have an indolent disease course and go undetected for some time. Patients may present clinically with a range of constitutional symptoms usually range from lymphadenopathy (the most common), night sweats, weight loss, weakness, and fever. Staging systems take into account a variety of factors, including lymphadenopathy, splenomegaly, hepatomegaly, and the presence and severity of cytopenias, while a patient’s prognosis is impacted by cytogenetic abnormalities and earlier progression of disease. Both the presentation and progression of CLL vary between patients, although patients with very-high-risk disease have a median survival of 19 months and a five-year overall survival of less than 24%.
Target Audience:
HCPs including but not limited to: medical oncologists and hematologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other healthcare professionals who commonly encounter patients with CLL.
Commercial Support Disclosure: This program is supported by educational grants from Beone Medicines USA.
This activity is free of charge.
Release Date: February 28, 2026 -- Expiration Date: February 28, 2027
Faculty: Tatyana Gavrilova, MD
Agenda
|
Introduction, disclosures |
|
CaDAnCe-101 trial |
|
Pirtobrutinib, venetoclax and obinutuzumab in Richter Transformation |
|
Pirtobrutinib vs ibrutinib in treatment naïve and R/R CLL |
|
Fixed duration pirtobrutinib, venetoclax, obinutuzumab in untreated CLL |
|
Fixed duration vs continuous therapy in untreated CLL |
|
Summary, conclusion, and best practice recap |
Learning Objectives
By the end of the session the participant will be able to:
- Review the most impactful findings presented at the ASH 2025 annual meeting related to CLL.
- Review new data on treatment of Richter transformation.
- Discuss updated results of the CaDAnCe-101 trial.
- Describe advances in novel agents and fixed duration therapy in untreated CLL.
Accreditation
ACCME Activity #203472941
ScientiaCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: ScientiaCME designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABIM MOC Credit Type: Medical Knowledge
Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.
Pharmacists
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-26-012-H01-P. This is an Application (A)-type activity.
Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.
Nurses: This activity is designated for up to 0.75 AMA PRA Category 1 Credit(s)™, and the American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ to meet the continuing education renewal requirements of nursing re-certification for APRNs and RN specialty. Some state nursing boards accept AMA PRA Category 1 Credit(s)™ for re-licensure requirements, some do not. Check your state board of nursing's CE requirements before applying credit from this course to your re-licensure.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 0.75 AMA PRA Category 1 Credit(s)™.
Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 0.75 AMA PRA Category 1 Credit(s)™.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosures of Faculty: Tatyana Gavrilova, MD, Associate Professor, Zucker School of Medicine at Hofstra/Northwell, has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL NOT discuss off-label uses of a commercial product.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Beone Medicines USA.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Combating rapid growth with durable response: navigating emerging therapies in extensive stage SCLC
From alpha to optimal: contemporary strategies for managing alpha thalassemia and its complications
Setting it straight: transformative therapeutics in the management of sickle cell disease